The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome

The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Pharmaceutical Sciences - Volume 114, 1 March 2018, Pages 24-29

Sofieke de Wilde, Maria G.H. de Jong, Alexander F. Lipka, Henk-Jan Guchelaar, Kirsten J.M. Schimmel,